Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

West Pharmaceutical Services Q3 2026 Results: Net Income $214M, Up 52.9% YoY

West Pharmaceutical Services reported net sales of $874.5 million for the third quarter of 2026, a 8.7% increase over the prior year. The company recognized a $55.7 million pre-tax gain from the sale of its SmartDose® 3.5mL On-Body Delivery System to AbbVie, contributing to a significant increase in net income to $214.0 million for the quarter.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue874.5804.6
Gross profit347.4294.3
Profit before tax267.7171.9
Net income214.0140.0
EPS (diluted, $ a share)$3.02$1.92

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+52.9%
Revenue, year on year+8.7%
Gross margin39.7%
Operating margin30.6%
Source

10-Q filed with the SEC, NYSE: WST. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

West Pharmaceutical Services Inc: key numbers

Share price
$417.80Close, Nov 16
Market cap
$29.1B
Shares outstanding
69.66MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from West Pharmaceutical Services Inc

All →
7:06 AM ET 8-K
Financial Results

West Pharmaceutical Services Financial Results

West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million, an 8.7% increase driven by strong organic growth in its High-Value Product (HVP) Components business. Due to the strong performance, the company raised its full-year 2026 net sales guidance to a range of $3.41 billion to $3.42 billion and its adjusted-diluted EPS guidance to $9.38 to $9.48.

Term
Q3 2026

“I am pleased to report strong third-quarter 2026 results, with net sales and adjusted EPS exceeding our expectations. Our results were again led by our High-Value Product (HVP) Components business. The robust sales performance drove strong operating income margin expansion and EPS growth. As a result of our team's strong execution in the third quarter, we are increasing our full-year 2026 guidance.”

Michel Lagarde, President and Chief Executive Officer

“I want to thank our global teams for their relentless focus on execution to deliver products and services for our customers and the patients they serve. West is a critical primary containment and drug delivery partner for pharmaceutical companies, biotechs and CDMOs around the world. We are grateful for the trust our customers put in us, and we remain committed to driving continuous improvement to even better serve their current and future needs.”

Michel Lagarde, President and Chief Executive Officer
5:16 PM ET 8-K
Loan & Debt

West Pharmaceutical Services $200M Debt Financing with Bank of America, N.A.

West Pharmaceutical Services entered into a new $950 million credit facility consisting of a $750 million revolving credit facility and a $200 million term loan. The proceeds were used to repay $130 million outstanding under its previous 2019 credit agreement, which was subsequently terminated. The new facility has a five-year term and will be used for working capital, capital expenditures, and general corporate purposes.

Value
$200M
Counterparty
Bank of America, N.A.
Term
5 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.